1. Home
  2. LYRA vs OSRH Comparison

LYRA vs OSRH Comparison

Compare LYRA & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • OSRH
  • Stock Information
  • Founded
  • LYRA 2005
  • OSRH N/A
  • Country
  • LYRA United States
  • OSRH United States
  • Employees
  • LYRA N/A
  • OSRH N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • OSRH
  • Sector
  • LYRA Health Care
  • OSRH
  • Exchange
  • LYRA Nasdaq
  • OSRH Nasdaq
  • Market Cap
  • LYRA 11.3M
  • OSRH 13.2M
  • IPO Year
  • LYRA 2020
  • OSRH N/A
  • Fundamental
  • Price
  • LYRA $7.51
  • OSRH $0.64
  • Analyst Decision
  • LYRA Hold
  • OSRH
  • Analyst Count
  • LYRA 1
  • OSRH 0
  • Target Price
  • LYRA $16.00
  • OSRH N/A
  • AVG Volume (30 Days)
  • LYRA 39.0K
  • OSRH 992.7K
  • Earning Date
  • LYRA 11-11-2025
  • OSRH 11-24-2025
  • Dividend Yield
  • LYRA N/A
  • OSRH N/A
  • EPS Growth
  • LYRA N/A
  • OSRH N/A
  • EPS
  • LYRA N/A
  • OSRH N/A
  • Revenue
  • LYRA $770,000.00
  • OSRH $104,735.00
  • Revenue This Year
  • LYRA N/A
  • OSRH N/A
  • Revenue Next Year
  • LYRA $123.83
  • OSRH N/A
  • P/E Ratio
  • LYRA N/A
  • OSRH N/A
  • Revenue Growth
  • LYRA N/A
  • OSRH N/A
  • 52 Week Low
  • LYRA $3.81
  • OSRH $0.45
  • 52 Week High
  • LYRA $37.50
  • OSRH $13.40
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 52.58
  • OSRH 45.31
  • Support Level
  • LYRA $6.55
  • OSRH $0.53
  • Resistance Level
  • LYRA $8.75
  • OSRH $0.76
  • Average True Range (ATR)
  • LYRA 0.54
  • OSRH 0.05
  • MACD
  • LYRA 0.15
  • OSRH 0.00
  • Stochastic Oscillator
  • LYRA 35.03
  • OSRH 34.59

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About OSRH OSR Holdings Inc. Common Stock

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

Share on Social Networks: